Upgrade to SI Premium - Free Trial

Express Scripts (ESRX) Reports In-Line Q1 EPS

April 28, 2015 4:08 PM

Express Scripts (NASDAQ: ESRX) reported Q1 EPS of $1.10, in-line with the analyst estimate of $1.10. Revenue for the quarter came in at $24.9 billion versus the consensus estimate of $24.34 billion.

Express Scripts sees Q2 2015 EPS of $1.39-$1.43, versus the consensus of $1.37.

"As our industry evolves, and plan sponsors have more business models to choose from, it is increasingly clear that Express Scripts is the best choice to manage America's pharmacy benefits," stated George Paz, Chairman and Chief Executive Officer. "At every turn, we add value to healthcare by combining a superior model of patient care with aggressive payer advocacy. Our unique combination of scale, client alignment and unmatched will, consistently creates greater value for patients and payers, while delivering solid results for our shareholders."

"Client retention starts with a simple concept: patient care," said Tim Wentworth, President. "Our model, which surrounds patients with clinically-rooted, data-driven specialized care, is embedded in our innovative solutions that are clearly differentiated and in high demand."

For earnings history and earnings-related data on Express Scripts (ESRX) click here.

Categories

Earnings Guidance Management Comments

Next Articles